Gastroenterology Division, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA.
Inflamm Bowel Dis. 2012 Jan;18(1):143-51. doi: 10.1002/ibd.21713. Epub 2011 Apr 11.
Abnormal innate immune response contributes to inflammatory bowel disease (IBD) and experimental mouse colitis. Colitis studies have focused primarily on key regulators of innate immunity, like pathogen recognition receptors and cytoplasmic mediators. Extracellular matrix (ECM) proteins are emerging as modulators of inflammatory responses by virtue of their interactions with pathogen-associated molecular patterns (PAMPs), cytokines, growth factors, receptors, and ECM fragments that mimic pathogens or cytokines. The ECM proteins have not been investigated in IBD at great depth from this standpoint. We have shown previously that the ECM protein lumican modulates host sensing of bacterial lipopolysaccharides (LPS) by Toll-like receptor (TLR) 4, and neutrophil chemotaxis via integrins.
Here we investigated the role of lumican in the development of colitis mediated by intrarectal administration of the hapten 2-4-5, trinitrobenzene sulfonic acid (TNBS) in Lum(+/+) and Lum(-/-) mice.
The TNBS treated Lum(+/+) mouse colons showed marked increases in CXCL1, tumor necrosis factor alpha (TNF-α), and neutrophil infiltration, whereas these responses were significantly dampened in the Lum(-/-) mice. The nuclear factor kappa B (NF-κB) transcription factor, known to regulate inflammatory genes, showed a robust increase after TNBS treatment in Lum(+/+) but not in Lum(-/-) colons. Also, nuclear translocation of NF-κB was delayed in LPS stimulated Lum(-/-) primary peritoneal macrophages.
The Lum(-/-) mice have low innate immune and inflammatory responses, but more severe body weight loss and tissue damage, a phenomenon seen in the innate immune impaired Tlr4(-/-) and MyD88(-/-) mice. Therefore, lumican promotes intestinal homeostasis by aiding innate immune and inflammatory responses that are beneficial in the early stages of colitis.
异常的先天免疫反应导致炎症性肠病(IBD)和实验性小鼠结肠炎。结肠炎研究主要集中在先天免疫的关键调节剂上,如病原体识别受体和细胞质介质。细胞外基质(ECM)蛋白因其与病原体相关分子模式(PAMPs)、细胞因子、生长因子、受体和模拟病原体或细胞因子的 ECM 片段的相互作用而成为炎症反应的调节剂。从这个角度来看,ECM 蛋白在 IBD 中并没有被深入研究。我们之前已经表明,ECM 蛋白亮氨酸拉链蛋白通过 Toll 样受体(TLR)4 调节宿主对细菌脂多糖(LPS)的感知,并通过整合素调节中性粒细胞趋化性。
在这里,我们研究了亮氨酸拉链蛋白在 Lum(+/+)和 Lum(-/-)小鼠经直肠给予半抗原 2-4-5、三硝基苯磺酸(TNBS)诱导结肠炎中的作用。
TNBS 处理的 Lum(+/+)小鼠结肠中 CXCL1、肿瘤坏死因子-α(TNF-α)和中性粒细胞浸润明显增加,而 Lum(-/-)小鼠的这些反应明显减弱。核因子 kappa B(NF-κB)转录因子,已知调节炎症基因,在 TNBS 处理后的 Lum(+/+)结肠中表现出强烈增加,但在 Lum(-/-)结肠中则没有。此外,LPS 刺激的 Lum(-/-)原代腹腔巨噬细胞中 NF-κB 的核易位延迟。
Lum(-/-)小鼠具有较低的先天免疫和炎症反应,但体重减轻和组织损伤更严重,这种现象在先天免疫受损的 Tlr4(-/-)和 MyD88(-/-)小鼠中也有出现。因此,亮氨酸拉链蛋白通过促进先天免疫和炎症反应来促进肠道内稳态,这些反应在结肠炎的早期阶段是有益的。